Introduction {#ncp10566-sec-0010}
============

Great difficulties are incurred by the clinicians charged with managing the patient with coronavirus disease 2019 (COVID‐19), as the result of several factors. First, the range of presentation spans an entire spectrum, from asymptomatic individuals who are not even aware that they have contracted the disease to the most critically ill patient treated in the setting of an intensive care unit (ICU).[^1^](#ncp10566-bib-0001){ref-type="ref"} Second, participation in the care of these patients impacts not only the professional life but also the personal life of those clinicians to an extent that none have ever experienced. And third, a plethora of new information regarding disease management is made available to these healthcare providers at an incredibly rapid rate and in a wide variety of formats, such as social media, news outlets, professional colleagues, personal experience, and international observational studies, but rarely in the form of trusted, peer‐reviewed randomized controlled trials (RCTs).

This report will discuss the scope of the COVID‐19 pandemic and delineate which principles of critical care nutrition apply to this disease process. Recommendations for the patient with COVID‐19 are surprisingly routine, similar to the nutrition therapy that would be provided to any critically ill patient. But more importantly, this article will delineate the constraints of this disease, which impact the choices clinicians are forced to make and limit clinicians' ability to deliver that nutrition regimen.

Scope of Disease {#ncp10566-sec-0020}
================

Regarding proper terminology, the disease is called COVID‐19. The virus itself is the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2).[^1^](#ncp10566-bib-0001){ref-type="ref"} The virus is in the family of coronavirus but appears to be unique to other members of that family seen previously. Predictive models estimate that ultimately 50%--60% of the world\'s population will be infected, with some questioning whether that number could approach 80%.[^2^](#ncp10566-bib-0002){ref-type="ref"} Similar pandemics have occurred around the globe in recent past. The SARS pandemic in 2002 had a mortality rate of 11%, whereas the Middle Eastern respiratory syndrome in 2012 had a mortality rate of 35%--50%.[^3^](#ncp10566-bib-0003){ref-type="ref"} In contrast, the mortality rate for COVID‐19 worldwide is estimated at around 4%, being slightly lower in the US at 2.3%.[^1^](#ncp10566-bib-0001){ref-type="ref"}, [^3^](#ncp10566-bib-0003){ref-type="ref"}

Never has the role of public health officials been more appreciated than what has been demonstrated in this pandemic, as these experts in communicable disease strive to protect the populace. Most impressive has been their directives on social distancing, which has been clearly shown to reduce exposure, slow the onslaught of new cases, and control the demands on our healthcare system. A key problem is the fact that there are asymptomatic carriers and a disease process with a long incubation time of 12--14 days and symptoms not becoming evident for 3--5 days postexposure.[^1^](#ncp10566-bib-0001){ref-type="ref"}, [^3^](#ncp10566-bib-0003){ref-type="ref"} Adequate testing is critical. It is important to know who has had the disease, who has not had it, and whether a person who has had the disease is now subsequently protected. It is still very early in this process, and time is needed to develop RCTs for therapy to know whether a vaccine will ever be developed against this organism and to understand the significance of antibody levels postinfection. Questions regarding whether antibodies in the convalescent serum of survivors afford protection in the future, whether that benefit falls off or erodes with time, and whether that effect can be used as therapy to treat others with more severe disease all need to be answered.

The wide range of susceptibility is a problem in itself.[^1^](#ncp10566-bib-0001){ref-type="ref"}, [^4^](#ncp10566-bib-0004){ref-type="ref"} At one end of this spectrum are young people who are much more likely to be asymptomatic from the infection, who seem to be (with few exceptions) protected from mortality, and who are less motivated to conform to the need for social isolation. At the other end of the spectrum is the elderly nursing home population, who appear most vulnerable, who experience a devastating effect from this disease process, and whose mortality rate exceeds 80%--85%.[^5^](#ncp10566-bib-0005){ref-type="ref"} The mortality rate does not go up appreciably until the fourth or fifth decade, continuing to climb with increasing age such that by the eighth decade, survival drops to \<10%--15%.[^5^](#ncp10566-bib-0005){ref-type="ref"} Overall, 80% of those infected will present as mild cases, with 50% of the total being completely asymptomatic. Approximately 20% have symptoms severe enough to require hospitalization, with 5% being critically ill and needing placement in the ICU, the majority of which (75%) will require mechanical ventilation.[^1^](#ncp10566-bib-0001){ref-type="ref"}, [^4^](#ncp10566-bib-0004){ref-type="ref"}

Age is the most important risk factor for contracting COVID‐19, but diabetes mellitus, hypertension, and obesity are also key factors in susceptibility.[^1^](#ncp10566-bib-0001){ref-type="ref"} The link between this respiratory disease and obesity may relate to the fact that the angiotensin‐converting enzyme 2 protein receptor site to which the SARS‐CoV‐2 binds is present on both the type 2 pneumocyte in the lungs and the adipocyte in adipose tissue. Other risk factors include multiple comorbidities and ethnicity, as shown by greater disease severity and higher mortality in African American and Hispanic populations. Early data also suggest that lower socioeconomic class increases risk, presumably because of reduced access to good medical care, poor dietary habits, and lower education with poorer understanding of the social distancing and interpersonal restrictions required to limit spread of the disease.[^1^](#ncp10566-bib-0001){ref-type="ref"}

Another aspect of this pandemic is the surge effect, the position of a community or healthcare institution on the curve of new cases and disease‐related deaths, and the steepness of that curve. With a steeper curve, a greater impact occurs regarding hospital bed capacity, options for treatment, available equipment, a sufficient number of healthcare providers, and the ability to deliver nutrition therapy.

There are many aspects of the patient with COVID‐19 that are different from the typical critically ill patient in an ICU with acute respiratory distress syndrome (ARDS). An overwhelming high infectivity exists for this disease. Humans are naïve and have never been exposed to this virus, and thus we are exquisitely sensitive. The major mode of transmission is aerosolized droplets, which means that coughing or sneezing can expel viral‐laden secretions for ≥4--5 feet (hence the 6‐foot rule for social distancing).[^6^](#ncp10566-bib-0006){ref-type="ref"} Up to 30% of infected patients will shed the SARS‐CoV‐2 virus in their feces, which adds the component of a fecal‐oral route of transmission for this disease.[^7^](#ncp10566-bib-0007){ref-type="ref"}, [^8^](#ncp10566-bib-0008){ref-type="ref"}

A good understanding of this unique pandemic is critical, as consideration for potential strategies of nutrition therapy must take into account recommendations from the Center for Disease Control and the World Health Organization for the management of every patient with this disease process. Those recommendations emphasize the need to provide clustered care, minimize exposure, and preserve use of personal protective equipment (PPE).[^3^](#ncp10566-bib-0003){ref-type="ref"} These concepts have tremendous implications for the nutrition support clinician. Hospital or ICU rooms dedicated to patients with COVID‐19 are sealed, and registered dietitians may be restricted from even entering the unit (in addition to physical and occupational therapists, pharmacists, etc). The frequency of interactions between the healthcare provider and the patient, meaning the number of times that provider enters the room, has to be minimized. Clustering of care means that the nurse batches together as many aspects of care as possible, enters the room once to deliver those therapies, and then exits until a subsequent time when another group of treatments is needed. For the non‐ICU patient in the ward, the nurse may enter only at the beginning, middle, and end of a long 8--12 hour shift.

The total number of healthcare providers that enter the sealed room of the patient with COVID‐19 needs to be limited as well. An effort is made to restrict all members of the primary team from entering the room, allowing instead for just a single representative, along with the nurse and only essential ancillary personnel. Every time the healthcare provider enters and exits the room, a new set of PPE (gown, gloves, eye ware, protective face shield, and N95 respirator) is used, with only a portion of that able to be reused for subsequent visits. In many units, the head of the bed is positioned closer to the door, which allows for the intravenous fluid pumps and computer for the electronic medical record to be placed in the hallway outside the patient\'s room. If pumps are left in the room, their alarms may not be heard through the closed sealed door, necessitating the use of baby monitors.

No aspect of nutrition therapy should increase exposure for the healthcare provider beyond that which is absolutely necessary. If supplements are ordered for protein, soluble fiber, or probiotics, they may need to be given together only once, or at most twice, per day. The practice of gastric residual volumes as a monitor for enteral nutrition (EN) should be eliminated. Ordering bolus feeding to be infused every 2 hours is not reasonable but instead should be given as "incidental syringe feeding" of a variable volume of formula every time the nurse enters the room to deliver clustered care. Energy requirements should be calculated by simple weight‐based equations, as use of indirect calorimetry would involve entry of more healthcare providers into the room and added equipment that has to be decontaminated. Similarly, techniques for achieving enteral access should avoid endoscopy or transport out of the ICU to a radiology suite for tube placement under fluoroscopic guidance. Placement of any feeding tube should be recognized as an "aerosol‐generating procedure," and if not performed by the most experienced intensivist trained with rapid intubation and use of PPE, switching earlier to parenteral nutrition (PN) should be considered.[^6^](#ncp10566-bib-0006){ref-type="ref"} Nutrition support clinicians should perform face‐to‐face assessment, not by entering the sealed room but by peering through the glass door or window to communicate with nursing service and visually confirm, as much as possible, the daily deferred physical exam performed originally by the primary team. Each hospital must make site‐specific changes to overcome the obstacles created by the constraints of this disease process.

Shortages have tremendous influence on what nutrition therapy is ultimately delivered. The sheer number of intravenous fluid pumps required to infuse antibiotics, vasopressor agents, sedatives, and other medications in a surge situation may result in an insufficient number of pumps to provide these therapeutic agents. These are the same pumps needed to infuse PN. Shortages may extend to involve the separate pumps required to deliver continuous infusion of enteral formula. Nutrition support clinicians instead have to improvise by switching to gravity drain or bolus infusion. With a shortage of mechanical ventilators, intensivists have had to resort to "co‐venting," in which 1 machine is used to simultaneously ventilate 2 separate patients. Although the Society of Critical Care Medicine (SCCM) does not recommend this strategy, the organization acknowledges that its use may be necessary in extreme surge situations.

The clinical consequences of COVID‐19 affect delivery of the prescribed nutrition regimen and impact the patient\'s ability to assimilate infused exogenous nutrients.[^1^](#ncp10566-bib-0001){ref-type="ref"} The most common unifying clinical presentation is a rapid, persistent refractory hypoxemic respiratory failure. The most critically ill patients with this disease process have an incredible hyperinflammatory response described as the cytokine storm syndrome. Laboratory tests confirm not only diffuse systemic inflammation, as suggested by high levels of C‐reactive protein and erythrocyte sedimentation rate, but also severe inflammation throughout multiple organ systems, as evidenced by elevated myoglobin (skeletal muscle), troponins (heart), aspartate aminotransferase/alanine aminotransferase (liver), and blood urea nitrogen/creatinine (kidney). With this cytokine storm comes a number of metabolic derangements that reflect futile substrate cycling, intolerance, and errors in fuel use. There is a severe insulin resistance due to not only predisposing diabetes mellitus and obesity but also the severe inflammatory process and cytokine storm. Patients with COVID‐19 are very sensitive to volume overload, so conservative fluid volume resuscitation is required. Patients tend to be hypernatremic because of insensible fluid loss from fever and inflammation, development of acute kidney injury (AKI), and an osmotic diuresis from glucosuria. A pseudohyponatremia effect from elevated glucose levels means that sodium levels may be even higher than what appears in the laboratory values. Hyperphosphatemia occurs because of muscle breakdown, mitochondrial failure, and progression to AKI. Hypocalcemia is common, as the high phosphate levels chelate available calcium. Hyperkalemia results from the catabolic response unless AKI develops with a renal tubular pathology, resulting in loss of potassium in the urine and a refractory hypokalemia. The severe insulin resistance leads to ketonemia and hypertriglyceridemia, made worse with infusion of soy‐based intravenous lipid emulsion (ILE) for PN or propofol for sedation. Over 85% of ICU patients with COVID‐19 are hypercoagulable, which accounts in large part for the ventilation/perfusion mismatch in the lungs leading to hypoxemia, the presentation of some patients with stroke and myocardial infarction, and the need for anticoagulation with heparin.[^9^](#ncp10566-bib-0009){ref-type="ref"} ICU patients with COVID‐19 tend to show severe deconditioning and immobilization, which lead to an accelerated proteolysis just short of rhabdomyolysis. It is anticipated that a postviral syndrome with debilitation will become apparent in those severely ill patients who manage to survive COVID‐19.

Overall Recommendations for Nutrition Therapy {#ncp10566-sec-0030}
=============================================

In mid‐March 2020, as the pandemic was just beginning to expand in this country, the SCCM released its Surviving Sepsis Campaign guidelines for the management of the patient with COVID‐19. When it was noted that no recommendations for nutrition therapy were included in these guidelines, a group of nutrition experts were recruited from SCCM and the American Society for Parenteral and Enteral Nutrition (ASPEN) to develop COVID‐19--specific recommendations for such support. Immediately evident was a paucity of data in the literature to make any recommendations specific to COVID‐19. So, instead, the group of experts compiled recommendations based on principles of critical care nutrition, modified by the constraints of this disease process, resulting in other words with COVID‐19--relevant recommendations for nutrition therapy.[^10^](#ncp10566-bib-0010){ref-type="ref"}

The basis for these recommendations was centered on the presumption that the most important aspect of nutrition therapy for severely ill patients with COVID‐19 was to bathe the intestinal mucosa with luminal nutrients, to maintain gut barrier defenses, to attenuate the systemic inflammatory response syndrome, and to support the microbiome.[^11^](#ncp10566-bib-0011){ref-type="ref"}, [^12^](#ncp10566-bib-0012){ref-type="ref"} Because the gastrointestinal tract is the largest immune organ in the body with the greatest microbial burden, the gut can act as an accelerator to the hyperinflammatory response seen in this disease process. On the flip side of this precept is an opportunity to use the gut through early EN to modulate immune responses, oppose dysbiosis, and promote an anti‐inflammatory pattern of recovery.[^10^](#ncp10566-bib-0010){ref-type="ref"}

Regarding actual recommendations for nutrition therapy in the patient with COVID‐19, the principles follow, in cookbook fashion, those for critical care nutrition in general for any ICU patient (see Figures [1](#ncp10566-fig-0001){ref-type="fig"}, [2](#ncp10566-fig-0002){ref-type="fig"}, [3](#ncp10566-fig-0003){ref-type="fig"}).[^13^](#ncp10566-bib-0013){ref-type="ref"}, [^14^](#ncp10566-bib-0014){ref-type="ref"}, [^15^](#ncp10566-bib-0015){ref-type="ref"} EN is preferred over PN. Intragastric EN should be initiated early after admission to the ICU, especially if the patient requires intubation and placement on mechanical ventilation. In most cases with acute deterioration of clinical status, the most experienced intensivist will expediently perform intubation, establish a central line, and often place a large bore orogastric or nasogastric tube at 1 setting. Patients should then be monitored for tolerance, as EN started at trophic doses is advanced slowly over the first week to goal for energy and protein provision. The biggest difference for the patient with COVID‐19 is that clinicians should lower their threshold for switching from EN to PN. Evidence of intolerance may harbor a greater danger of complications, such as ischemic bowel and the need for postpyloric tube placement, and would necessitate an additional aerosol‐generating procedure, and the need for noninvasive positive pressure ventilation might preclude use of a feeding tube altogether (because of difficulty establishing a seal or tight mask fit with a feeding tube in place). Once the decision is made, the actual delivery of PN for the patient with COVID‐19, again, is routine, following usual principles for critical care nutrition. The only exception would be the need to use strategies that avoid infusion of proinflammatory, pure soy‐based ILE for the first week after admission to the ICU, either by restricting use of ILE altogether or by switching to a less inflammatory mixture of lipids, such as SMOF (soy, medium‐chain triglycerides, olive oil, and fish oil) or olive oil--based ILE.[^13^](#ncp10566-bib-0013){ref-type="ref"}

![Nutrition recommendations for early enteral nutrition in patients with COVID‐19.[^10^](#ncp10566-bib-0010){ref-type="ref"} ABW, actual body weight; BMI, body mass index; EN, enteral nutrition; IBW, ideal body weight; ICU, intensive care unit; PN, parenteral nutrition.](NCP-9999-na-g001){#ncp10566-fig-0001}

![Nutrition recommendations for parenteral nutrition (PN) in patients with COVID‐19.[^10^](#ncp10566-bib-0010){ref-type="ref"} COVID‐19, coronavirus disease 2019.](NCP-9999-na-g002){#ncp10566-fig-0002}

![Additional recommendations to guide nutrition therapy for patients with COVID‐19.[^10^](#ncp10566-bib-0010){ref-type="ref"} COVID‐19, coronavirus disease 2019.](NCP-9999-na-g003){#ncp10566-fig-0003}

Nutrition Therapy During Prone Positioning {#ncp10566-sec-0040}
==========================================

COVID‐19 leads to severe ARDS in a relatively small number of those infected, estimated at 12% requiring mechanical ventilation (14% require ICU admission, of which 75% end up on mechanical ventilation \[or 12% of the total COVID‐19 patient population\]).[^1^](#ncp10566-bib-0001){ref-type="ref"} In the patients who develop refractory hypoxemia, prone positioning is an inexpensive technique to improve oxygenation and increase bronchial secretion clearance. Although some controversy still exists regarding the use of EN while patients are in the prone position, most literature now supports the concept that EN during prone positioning is safe and effective.[^16^](#ncp10566-bib-0016){ref-type="ref"}, [^17^](#ncp10566-bib-0017){ref-type="ref"} Voluntary prone positioning can be used when the patient is awake, can breathe spontaneously, and can self‐assist with the prone positioning. When the patient is heavily sedated or paralyzed and ventilated, a number of healthcare providers may be required to turn the patient into the prone position. Several retrospective and small prospective trials have shown that EN during prone positioning is not associated with increased risk of gastrointestinal or pulmonary complications.[^17^](#ncp10566-bib-0017){ref-type="ref"}, [^18^](#ncp10566-bib-0018){ref-type="ref"}, [^19^](#ncp10566-bib-0019){ref-type="ref"} Most patients in the prone position tolerate EN delivered into the stomach, but on occasion, postpyloric placement of the feeding tube may be indicated. Placement of postpyloric tubes increases exposure to SARS‐CoV‐2, and thus their use should be considered only on a case‐by‐case basis in patients with COVID‐19. When EN is introduced during prone positioning, elevating the head of the bed (reverse Trendelenburg) 10--25° may decrease the risk of aspiration, facial edema, and intra‐abdominal hypertension.[^20^](#ncp10566-bib-0020){ref-type="ref"}

Nutrition Therapy During ECMO {#ncp10566-sec-0050}
=============================

Extracorporeal Membrane Oxygenation (ECMO) is a supportive care strategy to oxygenate and ventilate patients with severe ARDS with refractory hypoxemia and/or hypercapnia.[^21^](#ncp10566-bib-0021){ref-type="ref"} No COVID‐19--specific data are currently available regarding delivery of nutrition therapy for the ECMO patient. One of the major obstacles to early EN for patients requiring ECMO is the perception that ECMO patients are at significant risk of delayed gastric emptying and bowel ischemia. Data from several observational trials and a review article support the safety and tolerability of EN delivery during ECMO.[^22^](#ncp10566-bib-0022){ref-type="ref"} Large database studies on prospectively collected data of several thousand patients report that early EN resulted in decreased mortality, with no significant increase in episodes of ischemic bowel.[^23^](#ncp10566-bib-0023){ref-type="ref"}, [^24^](#ncp10566-bib-0024){ref-type="ref"} Thus, early EN may be initiated during use of ECMO, starting at trophic doses, with slow advancement over the first week of critical illness in patients with COVID‐19.

Additional Nutrition Therapies {#ncp10566-sec-0060}
==============================

As COVID‐19 has spread across the globe, numerous untested nutrition strategies have been proposed and widely circulated on the internet and social media for the patient suffering from infection by the SARS‐CoV‐2 virus. Many of these nutrition strategies are not based on sound scientific principles. Caution and transparency must be used when providing suggestions from untested or unstudied nutrition agents to avoid being a detriment to patients and their families. In a fast‐moving pandemic, no therapeutic intervention for these patients should be driven by fear and misinformation, which often supersede the scientific evidence. The following nutrition interventions may be considered but are thought to be hypothesis‐generating, at best, for the COVID‐19 population.

Coronavirus, along with several other viruses, cause ≥30% of upper respiratory infections (URIs) in humans.[^25^](#ncp10566-bib-0025){ref-type="ref"} Although not specifically evaluated in COVID‐19, the use of probiotics for URIs has shown benefit. In a meta‐analysis of 12 studies comparing placebo vs probiotics, the probiotic‐supplemented groups showed fewer URIs and a decrease in the mean duration of URI symptoms when compared with the placebo groups. [^26^](#ncp10566-bib-0026){ref-type="ref"}

Inconsistency in the nutrition literature regarding supplementation of any of the B vitamins or vitamin E in viral illnesses in ICU care precludes any specific recommendations for their use in COVID‐19. Several protocols for the use of vitamin D in COVID‐19 have circulated on social media. Vitamin D has been shown to be beneficial in viral infection in certain animal models, as well as some very limited human studies.[^27^](#ncp10566-bib-0027){ref-type="ref"} Caution must be exercised, however, as 2 recent large ICU trials evaluating vitamin D supplementation in patients admitted to the ICU with documented deficiency of vitamin D reported no benefit.[^28^](#ncp10566-bib-0028){ref-type="ref"}, [^29^](#ncp10566-bib-0029){ref-type="ref"} Using an animal model (chickens), 1 study showed that a vitamin A--deficient diet led to increased susceptibility to coronavirus (not SARS‐CoV‐2),[^30^](#ncp10566-bib-0030){ref-type="ref"} whereas a second trial showed that supplementation with vitamin C increased resistance to coronavirus.[^31^](#ncp10566-bib-0031){ref-type="ref"} Both a meta‐analysis published in 2019 and a large prospective trial in septic ICU patients with ARDS reported no benefit from vitamin A supplementation in ICU patients.[^32^](#ncp10566-bib-0032){ref-type="ref"}

In the nutrition management of patients with COVID‐19, the trace minerals selenium and zinc have received the most attention. Selenium has been shown, in vitro and in some animal studies, to alter viral replication and reduce the viral‐induced oxidative stress. Selenium has well‐described benefits as a cofactor for several antioxidant enzymes, such as superoxide dismutase, thioredoxin reductase, and glutathione peroxidase. Again, as the overall data are inconsistent, consequently, no recommendation can be made for additional selenium other than the standard ICU recommendations found in the societal guidelines.[^13^](#ncp10566-bib-0013){ref-type="ref"}, [^15^](#ncp10566-bib-0015){ref-type="ref"} Adequate zinc is essential for the development and function of both the innate and humoral immune response. In vitro experiments have shown that zinc impairs viral replication and has beneficial effects on RNA viruses like coronavirus. Zinc supplementation in children documented to be deficient has been shown to decrease mortality from the measles virus, although data are inconsistent.[^33^](#ncp10566-bib-0033){ref-type="ref"}, [^34^](#ncp10566-bib-0034){ref-type="ref"} As with selenium, no recommendations for supplemental zinc, above the levels recommended for any ICU patient, can be supported until more data are available.

Conclusion {#ncp10566-sec-0070}
==========

Management of the patient with COVID‐19 must respect the need to cluster care, reduce the frequency of patient interactions, limit contamination of additional equipment, and avoid transport out of the ICU. Nutrition therapy follows the basic principles of critical care nutrition. Although most patients with COVID‐19 will tolerate intragastric EN, clinicians should maintain a lower threshold for switching from EN to PN, as the perception of gastrointestinal feeding intolerance may lead to increased exposure or the need for nonessential aerosol‐generating procedures. Provision of prebiotic fiber, probiotics, or added doses of protein is encouraged but should be given, if possible, by once‐daily supplementation. A paucity of data preclude making a firm recommendation for micronutrient supplementation at this time. All strategies involved in the nutrition therapy of the patient with COVID‐19 should be evaluated on the basis of the risk‐to‐benefit ratio, assessing risk both to the patient and to the healthcare provider.
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